NEW YORK (April 24, 2018)—The ATS Foundation announced its new ATS Foundation/ResMed Research Fellowship in Sleep-disordered Breathing and PAP Therapy.
The award will provide funding for two years in the amount of $100,000, provided by ResMed, a global provider of connected health with more than 4 million cloud-connected PAP devices monitoring patients every night.
SAN DIEGO (April 2, 2018)—ResMed announced the hire of its first chief technology officer (CTO), Bobby Ghoshal.
As CTO, Ghoshal will lead ResMed’s global health care informatics and data analytics team to drive its cloud-based digital health platforms, as well as investments in emerging health technologies such as artificial intelligence and machine learning.
NEW YORK (February 12, 2018)—Jeremy Orr, MD, of University of California, San Diego, has been awarded the new ATS Foundation/ResMed Research Fellowship in Noninvasive Ventilation (NIV) in COPD.
ResMed is a provider of NIV devices for treating COPD (chronic obstructive pulmonary disease) in the home and hospital.
Dr. Orr’s $100,000 award will support his research focused on the impact of noninvasive ventilation on cardiovascular biomarkers in COPD.
SAN DIEGO (January 25, 2018)—Switching from positive airway pressure (PAP) to adaptive servo ventilation (ASV) therapy can help patients with central sleep apnea be more adherent on therapy, according to a ResMed-funded study published in the Journal of Clinical Sleep Medicine (JCSM).
The study analyzed anonymous, aggregated data from the devices of 198,890 telemonitored U.S. patients with treatment-emergent central sleep apnea who started on PAP therapy, and found that:
SAN FRANCISCO (January 8, 2018)—ResMed today introduced Mobi, its first ResMed-branded portable oxygen concentrator (POC).
Mobi offers a balance of oxygen delivery, weight and battery life so that millions with chronic obstructive pulmonary disease (COPD) or other respiratory condition can enjoy ResMed-quality oxygen therapy at home or on the go.
SAN DIEGO (December 12, 2017)—ResMed today was named one of America’s top 100 corporate citizens for the second straight year by Forbes and JUST Capital, a nonprofit that analyzes and ranks companies based on how they serve the priorities of the American people.
ResMed ranked #76 among other large publicly traded U.S. companies and #2 in “Health Care Equipment & Services” when compared on issues including:
SAN DIEGO (December 6, 2017)—ResMed has been named a 2017 “Medtech Company of the Year” finalist by MD+DI, a news resource in the medical device and diagnostic industry.
SAN DIEGO (November 21, 2017)—CHEST, the publication of the American College of Chest Physicians, has published a ResMed study that shows patient engagement apps significantly improve adherence to positive airway pressure (PAP) therapy.
The research included more than 128,000 patients, making it the world's largest study to look at sleep apnea and self-monitoring.
ATLANTA (October 23, 2017)—Eight finalists in the 2017 Innovative HME Retail Product Awards, sponsored by HomeCare Magazine, took 3.5 minutes each on day one of Medtrade to state their case as to why their product was the best to boost cash sales.
Eight Finalists
ATLANTA (September 12, 2017)—Managing compliance for sleep apnea patients and increasing resupply revenue just got easier for home medical equipment (HME) providers, as Brightree today announced automated resupply enrollment for patients managed by both Brightree and AirView by ResMed.
ATLANTA (July 5, 2017)—Brightree LLC, a provider of cloud-based software to improve business and clinical performance of post-acute care organizations, announced today that it has acquired AllCall Connect, a provider of a live-calling solution for CPAP (continuous positive airway pressure) patient resupply.
SAN DIEGO, Calif. (April 25, 2017)—ResMed today unveiled its AirMini, the world’s smallest CPAP machine.
AirMini packs ResMed’s clinically proven CPAP (continuous positive airway pressure) technology along with its comfort and ease-of-use features into a sleek, portable, pocket-sized device ideal for traveling. The AirMini is available with ResMed’s proprietary AutoSet functionality as well as an innovative, built-in humidification system for patient comfort.
MARSEILLES, France and SAN DIEGO (April 6, 2017)—ResMed Inc. today announced that people with obstructive sleep apnea who develop central sleep apnea (CSA) are more compliant on therapy after they switch from continuous positive airway pressure (CPAP) therapy to adaptive servo-ventilation (ASV) therapy, according to the largest-ever analysis of patients with treatment-emergent CSA.
—via AAHomecare, WASHINGTON, D.C. (March 22, 2017)—As first reported in late January, CMS included bundling CPAP devices, related accessories, and services on a monthly basis for Round 2019 of competitive bidding for HME, starting with five new CBAs specific to CPAP products only.
ATLANTA (March 22, 2017)—Brightree a provider of cloud-based software for helping post-acute care companies improve business performance and patient outcomes, today announced that its home medical equipment (HME) billing and business management module has enhanced integration capabilities with AirView and myAir, ResMed’s cloud-based sleep and respiratory care patient management and patient engagement platforms.
The enhanced capabilities include:
SAN DIEGO (March 17, 2017)—In recognition of World Sleep Day, ResMed, a provider of sleep disorder diagnosis and treatment, has picked its top five sleep apnea research findings of 2016.
SAN DIEGO (February 13, 2017)—ResMed's global lead in remote patient monitoring kept growing in 2016, even as the industry itself continued to expand, according to the annual mHealth and Home Monitoring report released by independent technology analyst firm Berg Insight.
SAN DIEGO, Calif. and WINTER HAVEN, Fla. (January 24, 2017)—ResMed, BMC and 3B Medical, today announced they have agreed on a global settlement of all litigation between the parties. BMC and 3B will be permitted to sell their existing products in exchange for royalty payments to ResMed, and ResMed will make a one-time settlement payment to 3B to close the Florida litigation between the two parties. The settlement did not include an admission of liability or wrongdoing by any party.
SAN FRANCISCO (January 9, 2017)—ResMed announced today at the 35th annual J.P. Morgan Healthcare Conference that the U.S. Food and Drug Administration has cleared ResMed's AirMini, the world's smallest continuous positive airway pressure (CPAP) device.
ResMed's tiny yet fully-featured AirMini, to be launched later this year, is designed as a secondary CPAP, making it easier for people to continue their sleep apnea therapy while traveling.
